| Literature DB >> 26955368 |
Hugo Oliveira1, Diana Vilas Boas1, Stéphane Mesnage2, Leon D Kluskens1, Rob Lavigne3, Sanna Sillankorva1, Francesco Secundo4, Joana Azeredo1.
Abstract
The present study demonstrates the antibacterial potential of a phage endolysin against Gram-negative pathogens, particularly against multidrug resistant strains of Acinetobacter baumannii. We have cloned, heterologously expressed and characterized a novel endolysin (ABgp46) from Acinetobacter phage vb_AbaP_CEB1 and tested its antibacterial activity against several multidrug-resistant A. baumannii strains. LC-MS revealed that ABgp46 is an N-acetylmuramidase, that is also active over a broad pH range (4.0-10.0) and temperatures up to 50°C. Interestingly, ABgp46 has intrinsic and specific anti-A. baumannii activity, reducing multidrug resistant strains by up to 2 logs within 2 h. By combining ABgp46 with several organic acids that act as outer membrane permeabilizing agents, it is possible to increase and broaden antibacterial activity to include other Gram-negative bacterial pathogens. In the presence of citric and malic acid, ABgp46 reduces A. baumannii below the detection limit (>5 log) and more than 4 logs Pseudomonas aeruginosa and Salmonella typhimurium strains. Overall, this globular endolysin exhibits a broad and high activity against Gram-negative pathogens, that can be enhanced in presence of citric and malic acid, and be used in human and veterinary medicine.Entities:
Keywords: Acinetobacter baumannii; antibacterial activity; circular dichroism; mass spectrometry; phage endolysins
Year: 2016 PMID: 26955368 PMCID: PMC4768612 DOI: 10.3389/fmicb.2016.00208
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antibacterial activity of ABgp46 against several Gram-negative bacterial pathogens.
| Bacterial species | ABgp46/water | Origin/characteristics |
|---|---|---|
| 0.03 ± 0.02 | Reference strain (ATCC 15692) | |
| 0.14 ± 0.05 | Clinical strain | |
| 0.17 ± 0.12 | Reference strain (CECT 4782) | |
| 0.23 ± 0.26 | Reference strain (CECT 858) | |
| 0.18 ± 0.13 | Reference strain (ATCC 13182) | |
| Clinical strain (TI, AMC, TZP, CE, AZ, ME, AN, GM, NN, CP, PF, TS) | ||
| Clinical strain (TI, AMC, TZP, CE, AZ, ME, AN, GM, NN, CP, PF, TS) | ||
| Clinical strain (TI, AMC, TZP, CE, CEF, AZ, ME, GM, NN, CP, PF, TS) | ||
| Clinical strain (TI, AMC, TZP, CE, CEF, AZ, ME, GM, NN, CP, PF, TS) | ||
| 0.37 ± 0.19 | Clinical strain (TI, AMC, TZP, CE, CEF, AZ, ME, CP, PF) | |
| Clinical strain (TI, AMC, TZP, CE, CEF, AZ, ME, CP, PF) |
Combinatorial antibacterial activity of ABgp46 with outer membrane permeabilizers under different concentrations against Escherichia coli O157:H7.
| pH | OMPs | Molarity (mM) | PBS/OMPs | ABgp46/OMPs | ABgp46/OMPs |
|---|---|---|---|---|---|
| 7.0 ± 0.1 | EDTA | 0.50 | 0.27 ± 0.11 | 0.32 ± 0.15 | |
| Citric | 0.36 | 0.21 ± 0.14 | |||
| Malic | 0.60 | 0.24 ± 0.11 | 0.53 ± 0.28 | ||
| Lactic | 1.20 | 0.24 ± 0.14 | 0.55 ± 0.31 | ||
| Benzoic | 1.20 | 0.26 ± 0.15 | 0.49 ± 0.34 | ||
| Acetic | 1.20 | 0.25 ± 0.14 | 0.53 ± 0.30 | ||
| 5.5 ± 0.1 | Citric | 1.50 | 0.20 ± 0.13 | ||
| Malic | 3.30 | 0.17 ± 0.14 | |||
| Lactic | 3.45 | 0.31 ± 0.07 | - | ||
| Benzoic | 3.55 | 0.27 ± 0.13 | 0.44 ± 0.33 | ||
| Acetic | 4.35 | 0.26 ± 0.12 | 0.21 ± 0.22 | ||
| 4.0 ± 0.1 | Citric | 3.65 | 0.28 ± 0.06 | 0.15 ± 0.04 | |
| Malic | 4.55 | 0.24 ± 0.18 | 0.10 ± 0.03 | ||
| Lactic | 8.00 | 0.27 ± 0.18 | 0.15 ± 0.04 | ||
| Benzoic | 10.00 | 0.57 ± 0.58 | 0.02 ± 0.03 | ||
| Acetic | 20.00 | 0.22 ± 0.08 | 0.42 ± 0.29 | 0.11 ± 0.10 |
Combinatorial antibacterial activity of the best ABgp46/outer membrane permeabilizers (EDTA, citric, and malic acid) formula against broad range of planktonic Gram-negative pathogens.
| Bacterial species | ABgp46/EDTA | ABgp46/citric | ABgp46/malic |
|---|---|---|---|
| 0.32 ± 0.15 | |||
| 0.57 ± 0.20 | |||
| 0.26 ± 0.08 | 0.81 ± 0.12∗ |